ALCAM Antibody

1. multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors for primary diffuse pleural mesotheliomas PMID:28811252
2. Activated leukocyte cell adhesion molecule (ALCAM) has been implicated in tumorigenesis. PMID:29315254
3. this study establishes for the first time that CD166 is the ligand of ILT3. Blockade of CD166 by ILT3.Fc inhibited progression of human tumor cell lines in NOD.Cg-Prkdc Il-2rg/SzJ mice, suggesting its potential immunotherapeutic value. PMID:29263213
4. These data indicate that cardiac surgery influences the expression of CD162, CD166 and CD195 and that the intensity of the immune system response, displayed as the change in the CD162, CD166, CD195 expression, varies, depending on the surgical technique used. PMID:27625334
5. These findings indicate that high ALCAM expression is associated with poor prognosis and advanced clinicopathological characteristics in CRC patients. PMID:28537909
6. ALCAM is a potential mediator in the late complications of diabetes in the kidney. PMID:28325697
7. we show that although the histological detection of ALCAM within the tumor tissue correlates strongly with tumor stage in BCa (Figure (Figure2),2), it does not appear to be prognostic of overall survival. In contrast, urine ALCAM correlates with tumor stage and is a significant independent predictor of 3-year overall survival for patients after cystectomy. PMID:27894096
8. Our data indicate that Gal-8 interacts with ALCAM at the surface of breast cancer cells through glycosylation-dependent mechanisms. A novel heterophilic interaction between ALCAM and Gal-8 is demonstrated here, suggesting its physiologic relevance in the biology of breast cancer cells PMID:27130882
9. CD166 functions as a risk factor for cancers, and the alterations of its different functional isoforms were observed to correlate with specific or interplayed clinical outcomes. PMID:27398729
10. The results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis. PMID:27873306
11. MiR-148a and miR-152 can sensitize tamoxifen-resistant MCF-7 breast cancer cells to tamoxifen via downregulating ALCAM. PMID:28063929
12. CHIP directly regulates the stability of CD166 protein through the ubiquitin proteasome system. PMID:28279658
13. ALCAM is overexpressed on the surface of Human T-lymphotropic virus type 1-infected lymphocytes, both in chronically infected cell lines and in primary infected CD4(+) T lymphocytes. PMID:27252538
14. ALCAM is upregulated in pancreatic stellate cells of pancreatic cancer tissues, suggesting a potential role of ALCAM in regulating pancreatic cancer cell-pancreatic stellate cells interactions. PMID:27573419
15. PRMT1 is overexpressed in human melanoma, and may regulate tumor growth and metastasis via targeting ALCAM. PMID:27175582
16. SFMSCs increased through upregulation of the activated lymphocyte cell adhesion molecule (ALCAM) and N-cadherin by microRNA-192 and -218 downregulation, similar to BMMSCs and ADMSCs. PMID:28039611
17. Analysis of KRAS mutation combined with immunohistochemical expression of CD44 and CD166 identified subgroups of patients with colon adenocarcinoma at higher risk of lymph node involvement by the tumor and development of liver and lung metastasis. PMID:27062566
18. Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma PMID:27466504
19. CD166 antigen is specifically expressed on corneal endothelial cells. PMID:26902886
20. Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. PMID:25710579
21. The binding sites on CD6 and CD166 have been characterized to show that a SNP in CD6 causes glycosylation that hinders the CD6/CD166 interaction. PMID:26146185
22. a model that CD166 regulates MCAM through a signaling flow from activation of PI3K/AKT and c-Raf/MEK/ERK signaling to the inhibition of potential MCAM ubiquitin E3 ligases, betaTrCP and Smurf1 PMID:26004137
23. High ALCAM expression in melanoma cells of the primary tumor may indicate a more invasive phenotype. Low expression of ALCAM in regional lymph node metastases is a feature associated with unfavorable prognosis in patients with cutaneous melanoma. PMID:26134500
24. High ALCAM expression is associated with Invasive Cholangiocarcinoma. PMID:25987048
25. The Serum CD166 is a novel diagnostic tumor marker for hepatocellular carcinoma (HCC). PMID:25562819
26. Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation PMID:25395097
27. Differentially expressed/regulated cancer-related genes upon miR-125b expression along with the significant increase of ALCAM PMID:25539763
28. Low expression of ALCAM at sites of cell-cell contact in primary breast cancer tumors regardless of differentiation, size and lymph node involvement may contribute to the more aggressive phenotype of breast cancer among African-American women. PMID:25255861
29. an overexpression of CD166 was detected in the benign and malignant salivary gland tumors and its expression in the malignant tumor was associated with the aggressive behavior and tumor progression. PMID:25472586
30. ALCAM is generally expressed in normal and cancerous breast epithelium and that a marked reduction of ALCAM expression characterizes a subset of breast cancer patients with adverse tumor characteristics and unfavorable clinical outcome. PMID:25270339
31. Authors propose a framework for how ALCAMs contribute to DC-T-cell adhesion, stabilize DC-T-cell contacts and form a mechanical link between CD6 and the actin cortex to strengthen cell adhesion at the immunological synapse. PMID:24496453
32. CD14(+)CD16(+) monocytes selectively transmigrated across our BBB model as a result of their increased JAM-A and ALCAM expression. PMID:25420915
33. miR126-5p is a functional, endothelial-enriched microRNA that participates in the control of leucocyte trafficking by regulating the expression of ALCAM and SetD5. PMID:24562769
34. Migration of CD166 positive progenitor cells to sites of cartilage damage may be directed by regulation of DCC/CREB signaling. PMID:24966904
35. The expression of CD166 using immunohistochemistry in a large cohort of non-small cell lung cancer patients , was evaluated. PMID:24501004
36. These show high p21 and CD166 expression at the pretreatment biopsy were associated with tumor regression and poor prognosis in patients treated with 5-FU based chemoradiotherapy PMID:24708484
37. High ALCAM expression is associated with brain metastasis. PMID:24311639
38. An antibody drug conjugate was generated recognizing the CD166 antigen which was found to be strongly up-regulated in all AML cell lines and AML blasts of some patients PMID:24487095
39. CD166 affected-CD44 expression is dependent of transcription via blocking NF-kappaB pathway. On the contrary, CD44 promoted up-regulation of CD166 mRNA and protein. PMID:25094049
40. By directly targeting the Rho GDP dissociation inhibitor alpha (RhoGDI1) and activated leukocyte cell adhesion molecule (ALCAM). PMID:24710410
41. ALCAM stably interacts with actin by binding to syntenin-1 and ezrin. PMID:24662291
42. this work summarizes a novel link between CD166 and YAP, explores the interplay among related important signaling pathways, and may lead to more effective therapeutic strategies for liver cancer. PMID:24482231
43. Patients whose head and neck squamous cell carcinoma tumors expressed high levels of CD166 had a significantly poorer clinical outcome than those whose tumors expressed low levels of CD166. PMID:23903875
44. ALCAM expression and shedding is elevated in response to TGF-beta signaling. PMID:24385212
45. The entry of HIV infected and uninfected CD14(+)CD16(+) monocytes into the brain was facilitated by significantly increased surface JAM-A, ALCAM, CD99, and PECAM-1, as compared to CD14(+) cells that are CD16 negative. PMID:23922698
46. Data indicate that arylsulfonamide inhibited ADAM-17 with selectivity, and maintained inhibitory properties on sALCAM shedding. PMID:24044434
47. CD166 expression indicate advanced tumor load category and node-positive status in colorectal cancer specifically. [Meta-analysis] PMID:23940674
48. Loss of E-cadherin and beta-catenin with cytoplasmic ALCAM accumulation may play pivotal role in oral cancer development and progression. PMID:23840677
49. ALCAM can be taken forward for analysis in sera of patients with thyroid carcinoma to determine its applicability as a minimally invasive serum biomarker for TC aggressiveness and patient disease-free survival. PMID:23148625
50. retention of intact ALCAM was associated with improved survival PMID:23539446

Show More

Hide All

HGNC: 400

UNIGENE: Hs.591293

KEGG: hsa:214

STRING: 9606.ENSP00000305988

OMIM: 601662